Bayer has reformulated Leukine without EDTA, which has been linked with fainting.
Bayer HealthCare Pharmaceuticals has come out with a liquid Leukine (sargramostim) 500 mcg vial without EDTA (edentate disodium).
Bayer had withdrawn its EDTA version in January since it was associated with fainting. Now that a non-EDTA form is available, Bayer is discontinuing its special program that gave patients with the greatest medical need priority access to lyophilized Leukine 250 mcg vials, which do not contain EDTA. Leukine is approved to reduce life-threatening infections in older adults with acute myelogenous leukemia, the most common type of leukemia in this country. Bayer has sent a Dear Health Care Provider letter to oncologists and hematologists about this change.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, clickhere.